Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
SPNC's Cash to Debt is ranked higher than
81% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 4.48 vs. SPNC: No Debt )
SPNC' s 10-Year Cash to Debt Range
Min: 1   Max: No Debt
Current: No Debt

Equity to Asset 0.89
SPNC's Equity to Asset is ranked higher than
95% of the 367 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. SPNC: 0.89 )
SPNC' s 10-Year Equity to Asset Range
Min: 0.53   Max: 0.89
Current: 0.89

0.53
0.89
Interest Coverage 6.79
SPNC's Interest Coverage is ranked lower than
52% of the 204 Companies
in the Global Medical Devices industry.

( Industry Median: 117.58 vs. SPNC: 6.79 )
SPNC' s 10-Year Interest Coverage Range
Min: 1.05   Max: 9999.99
Current: 6.79

1.05
9999.99
F-Score: 5
Z-Score: 28.44
M-Score: -2.57
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 0.25
SPNC's Operating margin (%) is ranked higher than
62% of the 372 Companies
in the Global Medical Devices industry.

( Industry Median: 6.25 vs. SPNC: 0.25 )
SPNC' s 10-Year Operating margin (%) Range
Min: -34.35   Max: 4.35
Current: 0.25

-34.35
4.35
Net-margin (%) -0.23
SPNC's Net-margin (%) is ranked higher than
63% of the 372 Companies
in the Global Medical Devices industry.

( Industry Median: 4.71 vs. SPNC: -0.23 )
SPNC' s 10-Year Net-margin (%) Range
Min: -32.33   Max: 23.17
Current: -0.23

-32.33
23.17
ROE (%) -0.19
SPNC's ROE (%) is ranked higher than
63% of the 368 Companies
in the Global Medical Devices industry.

( Industry Median: 5.93 vs. SPNC: -0.19 )
SPNC' s 10-Year ROE (%) Range
Min: -55.34   Max: 22.1
Current: -0.19

-55.34
22.1
ROA (%) -0.17
SPNC's ROA (%) is ranked higher than
64% of the 382 Companies
in the Global Medical Devices industry.

( Industry Median: 3.43 vs. SPNC: -0.17 )
SPNC' s 10-Year ROA (%) Range
Min: -31.79   Max: 15.19
Current: -0.17

-31.79
15.19
ROC (Joel Greenblatt) (%) 0.89
SPNC's ROC (Joel Greenblatt) (%) is ranked higher than
63% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: 13.35 vs. SPNC: 0.89 )
SPNC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -94.79   Max: 27.62
Current: 0.89

-94.79
27.62
Revenue Growth (%) 4.60
SPNC's Revenue Growth (%) is ranked higher than
72% of the 301 Companies
in the Global Medical Devices industry.

( Industry Median: 5.00 vs. SPNC: 4.60 )
SPNC' s 10-Year Revenue Growth (%) Range
Min: -3.7   Max: 29.4
Current: 4.6

-3.7
29.4
EBITDA Growth (%) 46.00
SPNC's EBITDA Growth (%) is ranked higher than
97% of the 282 Companies
in the Global Medical Devices industry.

( Industry Median: -3.60 vs. SPNC: 46.00 )
SPNC' s 10-Year EBITDA Growth (%) Range
Min: -53.6   Max: 122.4
Current: 46

-53.6
122.4
EPS Growth (%) -70.50
SPNC's EPS Growth (%) is ranked lower than
53% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: -1.70 vs. SPNC: -70.50 )
SPNC' s 10-Year EPS Growth (%) Range
Min: -70.5   Max: 101.7
Current: -70.5

-70.5
101.7
» SPNC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

SPNC Guru Trades in Q2 2013

Chuck Royce 300 sh (New)
RS Investment Management 651,639 sh (New)
Jim Simons 87,100 sh (New)
Steven Cohen 78,087 sh (+8576.33%)
» More
Q3 2013

SPNC Guru Trades in Q3 2013

Paul Tudor Jones 19,600 sh (New)
Steven Cohen 647,209 sh (+728.83%)
Chuck Royce 300 sh (unchged)
RS Investment Management Sold Out
Jim Simons 64,000 sh (-26.52%)
» More
Q4 2013

SPNC Guru Trades in Q4 2013

Ron Baron 10,780 sh (New)
Jim Simons 70,222 sh (+9.72%)
Chuck Royce Sold Out
Paul Tudor Jones Sold Out
Steven Cohen 420,051 sh (-35.1%)
» More
Q1 2014

SPNC Guru Trades in Q1 2014

Ron Baron 36,980 sh (+243.04%)
Jim Simons 103,528 sh (+47.43%)
Steven Cohen 40,000 sh (unchged)
Steven Cohen 128,871 sh (-69.32%)
» More
» Details

Insider Trades

Latest Guru Trades with SPNC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ron Baron 2014-03-31 Add 243.04%$24.13 - $31.56 $ 25.65-6%36980
Ron Baron 2013-12-31 New Buy$17.2 - $25.43 $ 25.6520%10780
George Soros 2011-09-30 Sold Out 0.0012%$5.6 - $7.62 $ 25.65294%0
George Soros 2011-06-30 New Buy$4.68 - $6.21 $ 25.65359%13300
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.70
SPNC's P/B is ranked higher than
56% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 3.46 vs. SPNC: 5.70 )
SPNC' s 10-Year P/B Range
Min: 0.78   Max: 13.1
Current: 5.7

0.78
13.1
P/S 6.47
SPNC's P/S is ranked higher than
56% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 3.30 vs. SPNC: 6.47 )
SPNC' s 10-Year P/S Range
Min: 0.69   Max: 8.47
Current: 6.47

0.69
8.47
EV-to-EBIT -269.12
SPNC's EV-to-EBIT is ranked higher than
64% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 44.56 vs. SPNC: -269.12 )
SPNC' s 10-Year EV-to-EBIT Range
Min: 3.2   Max: 2801.8
Current: -269.12

3.2
2801.8
Current Ratio 8.19
SPNC's Current Ratio is ranked higher than
94% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 2.92 vs. SPNC: 8.19 )
SPNC' s 10-Year Current Ratio Range
Min: 1.4   Max: 8.52
Current: 8.19

1.4
8.52
Quick Ratio 7.70
SPNC's Quick Ratio is ranked higher than
94% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 2.16 vs. SPNC: 7.70 )
SPNC' s 10-Year Quick Ratio Range
Min: 1.2   Max: 7.99
Current: 7.7

1.2
7.99

Valuation & Return

vs
industry
vs
history
Price/Net Cash 10.90
SPNC's Price/Net Cash is ranked higher than
90% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. SPNC: 10.90 )
SPNC' s 10-Year Price/Net Cash Range
Min: 5.02   Max: 617.67
Current: 10.9

5.02
617.67
Price/Net Current Asset Value 8.60
SPNC's Price/Net Current Asset Value is ranked higher than
87% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. SPNC: 8.60 )
SPNC' s 10-Year Price/Net Current Asset Value Range
Min: 3.85   Max: 179
Current: 8.6

3.85
179
Price/Tangible Book 6.30
SPNC's Price/Tangible Book is ranked higher than
63% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 5.99 vs. SPNC: 6.30 )
SPNC' s 10-Year Price/Tangible Book Range
Min: 0.67   Max: 11.38
Current: 6.3

0.67
11.38
Price/DCF (Projected) 8.10
SPNC's Price/DCF (Projected) is ranked higher than
81% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. SPNC: 8.10 )
SPNC' s 10-Year Price/DCF (Projected) Range
Min: 5.23   Max: 336.5
Current: 8.1

5.23
336.5
Price/Median PS Value 1.70
SPNC's Price/Median PS Value is ranked higher than
56% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 1.20 vs. SPNC: 1.70 )
SPNC' s 10-Year Price/Median PS Value Range
Min: 0.18   Max: 1.95
Current: 1.7

0.18
1.95
Forward Rate of Return (Yacktman) -0.20
SPNC's Forward Rate of Return (Yacktman) is ranked higher than
73% of the 306 Companies
in the Global Medical Devices industry.

( Industry Median: 0.97 vs. SPNC: -0.20 )
SPNC' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -6.2   Max: -0.3
Current: -0.2

-6.2
-0.3

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:SC7.Germany
Spectranetics Corporation is incorporated under the laws of Delaware and formed in 1984. The Company develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. The Company has two operating segments that are identified on a geographic basis: (1) U.S. Medical and (2) International Medical. U.S. Medical and International Medical offer the same products and services but operate in different geographic regions, have different distribution networks and different regulatory environments. Its products are used to treat arterial blockages in the heart and legs and to remove pacemaker and defibrillator cardiac leads. Approximately 66% of its disposable product revenue is from products used in connection with its proprietary excimer laser system, the CVX-300. Its single-use laser catheters contain up to 250 small diameters, flexible optical fibers that can access difficult to reach peripheral and coronary anatomy and produce evenly distributed laser energy at the tip of the catheter for more uniform ablation. Its disposable products are focused in two categories: Vascular Intervention (VI) and Lead Management (LM). Vascular Intervention products include; support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices used in the treatment of peripheral arterial blockages, including chronic total occlusions, drug delivery catheters for vascular delivery of drugs and diagnostic agents. Lead Management products include: excimer laser sheaths; non-laser sheaths; and cardiac lead management accessories for the removal of pacemaker and defibrillator cardiac leads. Its competitors are manufacturers of products used in competing therapies within the peripheral and coronary atherectomy markets, such as: atherectomy and thrombectomy, using mechanical methods to remove arterial blockages, balloon angioplasty and stents, specialty balloon angioplasty, bypass surgery and amputation. The Company's products are medical devices subject to extensive regulation by the FDA under the Federal Food, Drug, and Cosmetic Act, or FDCA. FDA regulations govern.
» More Articles for SPNC

Headlines

Articles On GuruFocus.com
Baron Funds Comments on Spectranetics Corporation Feb 26 2014 
Spectranetics Corp. Reports Operating Results (10-Q) Nov 08 2010 
Spectranetics Corp. Reports Operating Results (10-Q) Nov 06 2009 
Spectranetics Corp. Reports Operating Results (10-Q) Aug 10 2009 
Spectranetics Corp. Reports Operating Results (10-Q) May 11 2009 
Spectranetics to Hold 2008 Fourth Quarter Financial Results Conference Call on February 19 Feb 12 2009 
Spectranetics Cross-Pilot Product Receives FDA Clearance Dec 15 2008 
Weekly CEO Buys Highlight: Spectranetics Corp., Noven Pharmaceuticals Inc., Dolan Media Company, Mod Sep 09 2008 

More From Our Partners
Spectranetics (SPNC) in Focus: Stock Rises 6.1% - Tale of the Tape Jul 25 2014 - ZACKS

More From Other Websites
Nasdaq stocks posting largest percentage decreases Jul 31 2014
Spectranetics to Present at the Canaccord Genuity 34th Annual Growth Conference Jul 30 2014
Spectranetics (SPNC) Highlighted As Today's Perilous Reversal Stock Jul 25 2014
Spectranetics (SPNC) in Focus: Stock Rises 6.1% Jul 25 2014
SPECTRANETICS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Other Events,... Jul 24 2014
Spectranetics Achieves Second Quarter 2014 Revenue of $43.6 Million Jul 24 2014
Spectranetics remains a top small cap pick, says Canaccord Jul 24 2014
Q2 2014 Spectranetics Earnings Release - After Market Close Jul 24 2014
Spectranetics Announces FDA Clearance of Peripheral Laser Atherectomy Devices for In-Stent... Jul 23 2014
Spectranetics receives FDA clearance of peripheral laser atherectomy devices Jul 23 2014
Spectranetics Announces FDA Clearance of Peripheral Laser Atherectomy Devices for In-Stent... Jul 23 2014
Spectranetics to meet or beat, remains a top small-cap idea, says Canaccord Jul 21 2014
AngioScore Launches New 200 mm Length AngioSculpt(R) Scoring Balloon Catheters Jul 09 2014
AngioScore Launches New 200 mm Length AngioSculpt(R) Scoring Balloon Catheters Jul 09 2014
Spectranetics to Hold 2014 Second Quarter Financial Results Conference Call on July 24 Jul 07 2014
SPECTRANETICS CORP Files SEC form 8-K, Completion of Acquisition or Disposition of Assets,... Jun 30 2014
Spectranetics Completes Acquisition of AngioScore Inc. Jun 30 2014
Volcano acquisition 'really smart,' says Barrington Jun 20 2014
Spectranetics (SPNC): Moving Average Crossover Alert Jun 18 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide